Stocks · News reference

Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385

Sep 8, 2026, 12:22 PMBenzinga Newsdesk

Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $385.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

The Motley FoolSep 8, 2026, 5:30 PMBrett Schafer
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)
Billionaire investor Stanley Druckenmiller holds positions in Amazon and Alphabet for AI infrastructure exposure, but his largest U.S. stock holding is Natera, a genetic diagnostics company that has returned approximately 10x since his initial investment in Q3 2022. Druckenmiller sold his Nvidia position in early 2024 due to valuation concerns and now holds Taiwan Semiconductor Manufacturing as his AI semiconductor bet instead.
AMZN GOOG GOOGL GOOGM GOOGN
BenzingaSep 1, 2026, 10:15 AMBenzinga Newsdesk
Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in
NTRA
BenzingaAug 27, 2026, 10:08 AMBenzinga Newsdesk
Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
NTRA